Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06651151
Title NeoLIPA: Neoadjuvant LTX-315 in Combination With Pembrolizumab in Resectable Stage III/IV Melanoma (NeoLIPA)
Acronym NeoLIPA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Oslo University Hospital
Indications
Therapies
Age Groups: adult | senior
Covered Countries NOR


No variant requirements are available.